Physician profile
Alex Seamon
NPI 1467614578
$13,839.74
in general payments reported to CMS, 2019-2025
36 companies · $29.03 in 2025
The $29.03 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,322 · 2020: $948 · 2021: $1,966 · 2022: $3,652 · 2023: $3,952 · 2024: $971 · 2025: $29.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,891 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,891.21 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,846.62 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,897.34 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,751.36 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,301.83 | 2019-2024 | Stelara |
| Qol Medical, LLC | $673.21 | 2019-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $530.34 | 2022-2025 | |
| Pfizer INC. | $510.87 | 2019-2024 | |
| Celgene Corporation | $485.84 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $383.84 | 2019-2024 | Rebyota |
| Daiichi Sankyo INC. | $325.25 | 2019-2024 | Injectafer |
| Gilead Sciences, INC. | $303.69 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $224.09 | 2019-2024 | Linzess |
| Ardelyx, INC. | $221.13 | 2022-2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $190.79 | 2020-2023 | Givlaari |
| Allergan, INC. | $154.66 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Seamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.